BRIEF published on 03/04/2024 at 08:05, 2 years 1 month ago Defence Therapeutics Gains Significant US Patent for Cancer-Killing AccuTOX® Technology Cancer Treatment Defence Therapeutics AccuTOX® Technology US Patent Antibody-drug Conjugates
PRESS RELEASE published on 03/04/2024 at 08:00, 2 years 1 month ago DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY Defence Therapeutics Inc. is granted a broad U.S. patent for its innovative cancer-killing AccuTOX technology, potentially providing market exclusivity until late 2042 Defence Therapeutics Inc. Broad U.S. Patent AccuTOX Technology Cancer-killing Market Exclusivity
PRESS RELEASE published on 11/07/2023 at 08:00, 2 years 5 months ago DEFENCE THERAPEUTICS KEY PLATFORM PATENT ACCEPTED BROADLY COVERING VACCINE TECHNOLOGY
PRESS RELEASE published on 10/25/2023 at 08:00, 2 years 6 months ago DEFENCE’S ACCUTOX® AND ANTIGEN CROSS-PRESENTATION: DISCOVERY LEADS TOWARDS THE DEVELOPMENT OF A GROUDNBREAKING PLATFORM
PRESS RELEASE published on 10/18/2023 at 08:00, 2 years 6 months ago Defence Therapeutics Inc.: DEFENCE’S NOVEL ACCUTOXTM CONTINUES TO SURPRISE ON RESULTS AGAINST CANCER
PRESS RELEASE published on 10/17/2023 at 08:00, 2 years 6 months ago Defence Therapeutics Inc.: DELIVERY OF ENCAPSULATED ACCUTOXTM-CHITOSAN NANOPARTICLES TRIGGERS COMPLETE TUMOR REGRESSION IN ANIMALS WITH PRE-ESTABSLIHED SOLID LYMPHOMA
PRESS RELEASE published on 10/10/2023 at 08:00, 2 years 6 months ago DEFENCE ANNOUNCES PEER-REVIEWED PUBLICATION OF ITS PRECLINICAL DATA ON ACCUM® AS AN ANTI-CANCER MOLECULE IN THE JOURNAL OF CANCER SCIENCE
PRESS RELEASE published on 09/25/2023 at 08:00, 2 years 7 months ago DEFENCE’S ACCUM®-mRNA LIPID NANOPARTICLES ELICIT ANTIBODY RESPONSE 2X STRONGER THAN STANDARD mRNA VACCINES
PRESS RELEASE published on 09/12/2023 at 08:00, 2 years 7 months ago DEFENCE’S BROAD AND VERSATILE ACCUM® TECHNOLOGY PLATFORM FOCUS ON CANCER THERAPEUTICS
PRESS RELEASE published on 09/05/2023 at 08:00, 2 years 7 months ago DEFENCE’S INNOVATIVE THERAPEUTICS FEATURED ON VIEWPOINT WITH DENNIS QUAID
Published on 05/02/2026 at 00:50, 28 minutes ago CoTec Announces Annual Stock Option, Restricted Share Unit And Deferred Share Unit Grants
Published on 05/02/2026 at 00:00, 1 hour 18 minutes ago Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration
Published on 05/02/2026 at 00:00, 1 hour 18 minutes ago Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Published on 05/01/2026 at 22:30, 2 hours 48 minutes ago Nextech3D.ai Appoints New Independent Auditor
Published on 05/01/2026 at 22:30, 2 hours 48 minutes ago Integrated Rewards Achieves SOC 2 Compliance to Support Enterprise-Scale Growth Across Canada's Card-Linked Rewards Network as EQ Closes Convertible Debt Financing
Published on 05/01/2026 at 19:23, 5 hours 54 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/01/2026 at 17:45, 7 hours 32 minutes ago Burkhalter Group acquires Progressio Holding GmbH and anplaq ag, Tamins (GR)
Published on 05/01/2026 at 17:21, 7 hours 56 minutes ago Fuller, Smith & Turner PLC: Total Voting Rights and Treasury Shares
Published on 04/30/2026 at 20:00, 1 day 5 hours ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 1 day 6 hours ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 1 day 6 hours ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 1 day 7 hours ago Minutes of the Combined General Meeting held on April 30, 2026
